Model-optimized bispecific antibodies improve the selectivity of antibody–drug conjugates for tumors
Academia Drug Development and Pharmacotherapy · 21.07.2026 · 2 (3)
DOI: 10.20935/acaddrug8407 ↗Kurz gefasst
Fachartikel in der Zeitschrift Academia Drug Development and Pharmacotherapy, online erschienen am 21.07.2026. Verfasst von Madison Stoddard und 4 weiteren Autor:innen. Die Arbeit nennt 43 Literaturangaben.
Abstract (Originalsprache)
Introduction
Antibody–drug conjugates (ADCs) direct chemotherapeutic payloads to tumors using antibodies targeting tumor-associated proteins. Despite this, ADC efficacy remains constrained by toxicity, some of which is driven by ADC binding to non-tumor tissues expressing the ADC’s target. For example, anti-human epidermal growth factor receptor 2 (HER2) ADCs can induce serious cardiac toxicity related to HER2 expression in the heart, and glembatumumab vedotin causes severe rash plausibly due to expression of its target, glycoprotein non-metastatic melanoma protein B (gpNMB), in the skin. Improving the selectivity of ADCs for tumors relative to non-tumor tissue could widen the therapeutic window of these drugs. Here we show that with careful optimization, bispecific ADCs (bsADCs) can improve tumor selectivity. Materials and methods: To investigate the impact of dual targeting on improving the tumor selectivity of bsADCs, we developed a mechanistic pharmacokinetic/receptor occupancy (PK/RO) model that accounts for antibody affinity and avidity. This model quantitatively predicts on-tumor and off-tumor target binding for bsADCs as a function of bsADC pharmacokinetics, target properties, and antibody binding affinity.
Results
Bispecific antibodies can only enhance tumor selectivity of ADCs compared to healthy target-expressing tissues when the affinities for both targets are properly optimized. The extent of bsADC tumor selectivity depends on the on- and off-rates for target binding. This four-dimensional search space is best explored using a computational model, as we have developed here. Improvements in ADC tumor selectivity remain robust to an order of magnitude of variation in target expression levels.
Conclusions
Bispecific antibodies may improve targeting specificity of ADCs, but it is critical to optimize affinities for the two tumor-associated antigens with the aid of mathematical modeling. This can improve the ratio of target-mediated on-tumor to off-tumor ADC engagement compared to single-target ADCs. The approach presented here provides a practical method of model-guided optimization of dual targeting, which may have broader applicability across antibody-based therapeutics.
Zitieren
APA
Stoddard, M., Panday, S., Gardner, H., Wyant, T., & Chakravarty, A. (2026). Model-optimized bispecific antibodies improve the selectivity of antibody–drug conjugates for tumors. Academia Drug Development and Pharmacotherapy, 2(3). https://doi.org/10.20935/acaddrug8407
Vancouver
Stoddard M, Panday S, Gardner H, Wyant T, Chakravarty A. Model-optimized bispecific antibodies improve the selectivity of antibody–drug conjugates for tumors. Academia Drug Development and Pharmacotherapy. 2026;2(3). doi:10.20935/acaddrug8407
BibTeX
@article{Stoddard2026,
author = {Stoddard, Madison and Panday, Sheetal and Gardner, Humphrey and Wyant, Timothy and Chakravarty, Arijit},
title = {Model-optimized bispecific antibodies improve the selectivity of antibody–drug conjugates for tumors},
journal = {Academia Drug Development and Pharmacotherapy},
year = {2026},
volume = {2},
number = {3},
doi = {10.20935/acaddrug8407}
}
EUVIMED